Monitoring NAMS open interest helps you see where real money is positioned on NewAmsterdam Pharma Company NV's options and which strikes are attracting the most commitment from traders. NewAmsterdam Pharma Company NV's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor NAMS options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising NAMS options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect NewAmsterdam Pharma Company NV to settle.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where NAMS open interest is concentrated. Our scanner maps NewAmsterdam Pharma Company NV's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade NewAmsterdam Pharma Company NV's options open interest as the signal it is, not as an afterthought.
